Synta Pharmaceuticals terminating its Phase III trial in second-line treatment of non-small cell lung cancer (NSCLC) is disappointing. Ergomed could still potentially benefit from a share of product revenues from ganetespib (Synta’s candidate cancer drug) in additional indications. Ergomed also has four other do-development deals which continue to offer potentially very attractive returns with clinical data from three of them due in 2016. We continue to favour Ergomed’s hybrid business model of ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Co-development partner Synta terminates Phase III trial in NSCLC
- Published:
21 Oct 2015 -
Author:
Sheena Berry -
Pages:
3
Synta Pharmaceuticals terminating its Phase III trial in second-line treatment of non-small cell lung cancer (NSCLC) is disappointing. Ergomed could still potentially benefit from a share of product revenues from ganetespib (Synta’s candidate cancer drug) in additional indications. Ergomed also has four other do-development deals which continue to offer potentially very attractive returns with clinical data from three of them due in 2016. We continue to favour Ergomed’s hybrid business model of ....